Kłusek M, Chawrylak K, Kuszneruk J, Kubas M, Krzemińska K. Sodium–glucose co-transporter-2 inhibitors - empagliflozin and dapagliflozin as future therapy for Alport Syndrome, literature review. Qual Sport [Internet]. 2024 Jul. 25 [cited 2024 Jul. 26];18:53252. Available from: https://apcz.umk.pl/QS/article/view/53252